Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 167.50 165.00 170.00 167.50 167.50 167.50 32,976 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 49.2 -56.5 -72.8 - 300

Amryt Pharma Share Discussion Threads

Showing 6601 to 6624 of 6675 messages
Chat Pages: 267  266  265  264  263  262  261  260  259  258  257  256  Older
DateSubjectAuthorDiscuss
08/5/2021
10:50
There was a great interview a few years ago in an Irish paper with Ray Stafford about Amryt. He was quoted as saying he advised Joe Wiley to "build it slowly and steadily", it always stuck with me...
alphabravo321
08/5/2021
09:51
Thanks to both delta & Diamondstar. When first reading the report and the acquisition I was confident that we’re in a good place. The share price fall is a little baffling to me but I’m hanging on tight! Cheers
bazworth
07/5/2021
20:25
By the way.. read every pharma newsletter.. not finance related.. but pharma write ups by those in the industry.. all saying amryt have done a blinder of a deal.. one even calling the eventual outfit an orphan drug "powerhouse"
delta0091
07/5/2021
20:16
Max payout if cvrs Cindy into play is $85m. Hardly a big deal considering market cap will be approaching $1b
delta0091
07/5/2021
19:15
I've already put the proceeds of my sale, richpassi, of the AMYT shares I sold Wednesday into GPM and GCL, investment trusts specialising in precious metals miners and uranium miners respectively. I go by the charts these days, richpassi, particularly the Ichimoku charts and tend to stick to investment trusts. Charts for investment trusts are more reliable than for individual companies. However I will end up with AMYT shares even if I don't buy any because if the CVR's become of value I can't imagine that AMYT will dish out hard cash to CVR holders, rather they will issue shares instead.
papillon
07/5/2021
18:47
Hang on in there Pap ;) can understand your frustration, its giving me a complex as I'm sure it will rise the second I push the sell button ! Signed Jonah ;)
richpassi
07/5/2021
18:08
It's always jam tomorrow with AMYT. Long term the future is bright for AMYT, but I could be dead before that bright future arrives. Consequently I sold my remaining paltry 500 AMYT shares before today's late drop in the share price I have the CVR's, so I still have skin in the game and will continue to monitor the AMYT share price and chart with a view to buying back in sometime (assuming I haven't kicked the bucket in the meantime).
papillon
07/5/2021
17:00
Post from diamond on LSE (thanks diamond)let me try to explain why Amryt paid 300 million for 1.8 million in revenue. Firstly, MYCAPSSA was only launched recently in USA, about 6 months ago. Hence, the USD 1.8 million revenue likely represents 100 acromegaly patients already on the drug.By the end of this year, I would expect 300 patients on the drug, which would represent an annual revenue of up to USD 18 million. At the moment, it looks like they may be getting 10% market penetration, as 3000 new acromegaly patients are diagnosed in USA/year. In addition, there are 25,000 existing acromegaly patients in USA at present, who may switch from injectable octreotide/Lanreotide to MYCAPSSA.Within 2-3 years, I believe that a target of 1000 patients on MYCAPSSA in USA could easily be achieved. With EU approval, the number could be easily doubled to 2000 patients (which would represent USD 120 million annual revenue). Within 3-5 years, I believe annual sales of USD 200-300 million is achievable.Further uplift in this figure could be achieved if 1) The market penetration in the newly diagnosed acromegaly population is higher eg 20% 2) More patients decide to convert from injectable to oral somatostatin therapy 3) Amryt achieves approval in GEP-NET indication (whereby revenues could easily be doubled).
digadee
06/5/2021
16:34
Current Nasdaq ADS price is $10.99. That equates to £1.59 per AMYT share. There is chart support around 160p, which was the very temporary low of last September.
papillon
06/5/2021
12:09
Agreed. The FDA seems to have gotten tougher this year. I got absolutely ruined with the recent CRL for Acadia.. I am hoping they can clear up the mess and recoup some of my losses!
whatno
06/5/2021
11:37
Yes, I am optimistic that some buy recommendations for Amryt will come both in US and U.K. Short term - Amryt share price has taken a hit, because it had to pay ‘fair value’ to buy Chiasma & an approved FDA drug, but FDA approval actually de-risks this deal. I am sure there were other interested parties in Chiasma - probably other US-based orphan drug companies. Ipsen or Novartis could have easily bought the company with their spare change from annual Lanreotide and Octreotide sales.
diamondstar1
06/5/2021
11:02
Thanks for the commentary Diamondstar. I hope that some of the US analysts feel the same way and we get some decent buy recommendations to support the share price.
whatno
06/5/2021
10:52
Hi baz Yes been in and out of FTC a few times. Out at present
volsung
06/5/2021
10:50
I'm a little baffled by the drop. I have sufficient that I will hold onto very tightly indeed...!! All fingers firmly crossed! The Directors hold a very healthy number of shares and I cannot think that they would agree to a deal that would harm their own interests. Volsung - I see we also would appear to share an interest in FTC!! (Sorry - well off-topic!)
bazworth
06/5/2021
10:49
Some assurances here - my instinct tells me that Chiasma was a good purchase at $297 million USD. Octreotide has annual sales of over 1 billion USD; Lanreotide has annual sales of 1 billion Euro (or roughly 800 million USD). This revenue is coming from 2 main indications:- acromegaly and GEP-NET. Hence, I believe that an annual sales for Mycapssa (an oral octreotide) of 200 million USD is a realistic figure for Amryt, with higher targets if approval in GEP-NET is achieved. Currently, most acromegaly patients are receiving octreotide or lanreotide injections once-monthly, and I believe that a proportion of patients would welcome the option of oral dosing.
diamondstar1
06/5/2021
10:30
Bought a few more. Buy when theres blood on the streets
volsung
06/5/2021
08:27
Currently 3rd biggest percentage faller according to advfn.
papillon
06/5/2021
08:09
I'm thanking my lucky stars I only kept 500 AMYT shares after selling most yesterday at circa £2.The share price has opened up well down this morning in line with the Nasdaq price. Like General MacArthur, "I will return", but only when the AMYT Ichimoku chart turns bullish again, whenever that will be.
papillon
05/5/2021
18:07
Having listenned to the conf call earlier, it's pretty clear that there's significant overlap that will allow cost savings to be made in the combined operation. The big factor for Chiasma is presumably that Amryt will accelerate the launch of their product in the US and provide a sales organisation for ex-US thereby avoiding the need to cut a deal with partners or fund an ex-US sales team. I also assume they are somewhat cash constrained so being part of the larger entity helps with cashflow and allows increased investment in product development. There were some interesting points made about combining Myalepta with Chiasma's oral platform technology which could provide very interesting lifecycle mamagement. Chiasma's CEO and other senior execs were on the call. I guess they will be casualties of the cost savings in due course!
whatno
05/5/2021
18:07
Competing with or bought out by...!
alphabravo321
05/5/2021
17:52
Thanks for that information, diamondstar. There was a very informative post on the lse bb today about Chiasma and the financial impact to AMYT of today's deal. I'll copy and paste it later on.
papillon
05/5/2021
17:43
The strategy to purchase Chiasma is 100% a Joe Wiley decision. Being a Neurologist- he has been looking for Acromegaly assets from the start. I hope his instincts are right - that oral dosing with somatostatin analogue is the way forward. He will be fighting against the big boys in the acromegaly space - Amryt will be competing against Novartis Octreotide and Ipsen’s Lanreotide.
diamondstar1
05/5/2021
16:46
I was initially sceptical, having done some reading, I think the issues Chimasa has can be solved by Amryt and this could turn out to be a serious stroke...I will follow the big money and hold very tight
alphabravo321
05/5/2021
16:30
The current Nasdaq ADS price, what no, is equivalent to £1.75 per AMYT share. Unless the ADS price recovers I see the AMYT share price falling further.
papillon
Chat Pages: 267  266  265  264  263  262  261  260  259  258  257  256  Older
ADVFN Advertorial
Your Recent History
LSE
AMYT
Amryt Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210620 21:06:23